New lung drug interaction study launches in healthy volunteers
NCT ID NCT07229716
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-stage study is testing a new drug called HRS-9813 in 20 healthy adults to see how it interacts with two existing medicines for pulmonary fibrosis (pirfenidone and nintedanib). The goal is to measure drug levels in the blood and check for side effects. This study does not treat any disease and is designed to gather safety and drug interaction information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, Fourth Military Medical University
RECRUITINGXi’an, Shanxi, 710026, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.